Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E20.68 EPS (ttm)18.21 Insider Own19.40% Shs Outstand106.73M Perf Week1.12%
Market Cap40.18B Forward P/E14.46 EPS next Y26.04 Insider Trans-0.48% Shs Float80.15M Perf Month8.07%
Income2.09B PEG2.69 EPS next Q6.88 Inst Own73.80% Short Float2.94% Perf Quarter31.67%
Sales7.62B P/S5.27 EPS this Y57.40% Inst Trans-0.10% Short Ratio3.04 Perf Half Y21.04%
Book/sh96.02 P/B3.92 EPS next Y9.14% ROA16.60% Target Price387.36 Perf Year-0.55%
Cash/sh26.96 P/C13.96 EPS next 5Y7.69% ROE22.30% 52W Range271.37 - 442.00 Perf YTD0.78%
Dividend- P/FCF20.13 EPS past 5Y40.30% ROI24.90% 52W High-14.84% Beta1.19
Dividend %- Quick Ratio3.50 Sales past 5Y26.10% Gross Margin92.20% 52W Low38.71% ATR9.06
Employees7400 Current Ratio4.00 Sales Q/Q23.10% Oper. Margin29.50% RSI (14)70.00 Volatility2.77% 2.39%
OptionableYes Debt/Eq0.07 EPS Q/Q15.80% Profit Margin28.10% Rel Volume1.28 Prev Close372.16
ShortableYes LT Debt/Eq0.07 EarningsNov 05 BMO Payout0.00% Avg Volume776.73K Price376.42
Recom2.40 SMA204.28% SMA5014.12% SMA20014.77% Volume993,311 Change1.14%
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
May-21-19Initiated Credit Suisse Neutral $336
May-08-19Reiterated Canaccord Genuity Hold $408 → $353
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Dec-13-19 09:50PM  Edited Transcript of REGN earnings conference call or presentation 5-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
10:29AM  Biotech Stocks Are Poised to Rise in 2020, Analyst Says. Here Is His Top Pick. Barrons.com
Dec-12-19 12:46PM  Regeneron Pharmaceutical Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
10:15AM  Society for Science & the Public Announces Regeneron as New Title Sponsor of the International Science and Engineering Fair PR Newswire
07:00AM  Regeneron and Cold Spring Harbor Laboratory Unveil New Dedicated Laboratories for Student Science Education PR Newswire
Dec-11-19 09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
09:14AM  Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent Zacks
07:17AM  These are the 20 best-performing stocks of the past decade, and some of them will surprise you MarketWatch
Dec-10-19 04:08PM  Why This Pharmaceutical Stock Broke Out Bullishly In Early Action Investor's Business Daily
12:28PM  Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations Benzinga
09:03AM  Regeneron shares fall on Sanofi's new direction MarketWatch
08:55AM  Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research Zacks
08:29AM  Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) PR Newswire
08:06AM  Dow Jones Futures: Stock Market, Apple On China Trade War Watch; Boeing, MongoDB, Stitch Fix Move On News Investor's Business Daily
06:38AM  Sanofis CEO Quits Diabetes as Cancer Breakthroughs Beckon Bloomberg
Dec-09-19 04:31PM  Regeneron Reports Initial Data for Multiple Myeloma Drug Zacks
Dec-08-19 09:00AM  First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma PR Newswire
Dec-07-19 08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 09:21AM  Regeneron Reports Positive Data on Rare Blood Disorder Drug Zacks
Dec-05-19 11:31AM  Why Is Regeneron (REGN) Up 14% Since Last Earnings Report? Zacks
07:00AM  Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder PR Newswire
Dec-04-19 08:33PM  Did Hedge Funds Drop The Ball On Regeneron Pharmaceuticals Inc (REGN) ? Insider Monkey
09:11AM  The stock market's biggest winners and losers of the past decade Yahoo Finance
Dec-03-19 07:31AM  Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal TheStreet.com
Nov-29-19 09:34AM  Alnylam Gets Second Product Approval Amid Stiff Competition Zacks
08:48AM  China Negotiates Bargain Prices With Big Pharma Barrons.com
Nov-28-19 09:30AM  REGN or BMRN: Which Is the Better Value Stock Right Now? Zacks
07:09AM  Esperion's Promising Drugs Under Review, Funds a Concern Zacks
Nov-27-19 05:00PM  New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths PR Newswire
Nov-22-19 08:14AM  Cancer-killing virus designer Vyriad raises $24.4 million American City Business Journals
07:00AM  Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award PR Newswire
Nov-20-19 09:50AM  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals Zacks
Nov-19-19 10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
09:31AM  Zacks.com featured highlights include: Brinker International, Sonic Automotive, Fulgent Genetics, Hewlett Packard and Regeneron Pharmaceuticals Zacks
Nov-18-19 08:06AM  Buy These 5 Top-Ranked Stocks With Upgraded Broker Ratings Zacks
Nov-15-19 12:30PM  Drug giant Roche acquires Lexington biotech for $390M American City Business Journals
Nov-14-19 10:04AM  Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study Zacks
Nov-13-19 10:03AM  Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus Zacks
Nov-12-19 09:30AM  REGN or BMRN: Which Is the Better Value Stock Right Now? Zacks
08:05AM  Merck's Ebola Vaccine Gets Conditional Approval in Europe Zacks
07:30AM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
Nov-11-19 09:15AM  Celgene (CELG) Hits 52-Week High, Can the Run Continue? Zacks
08:56AM  U.S. company directors compensated more than ever, but now risk backlash Reuters
08:16AM  Have Insiders Sold Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Recently? Simply Wall St.
Nov-08-19 09:13PM  CORRECTED-INSIGHT-US company directors compensated more than ever, but now risk backlash Reuters
03:42PM  US Stocks Mixed on Friday GuruFocus.com
12:49PM  The Dow Is Down 38 Points Because Trump Hasnt Agreed to Remove Tariffs Barrons.com
10:34AM  The Zacks Analyst Blog Highlights: Alibaba, General Electric, Anthem, Progressive and Pharmaceuticals Zacks
10:18AM  Short Seller Scores Big Win as Tiny Biotech Stock Sinks 72% Bloomberg
08:24AM  Biotech Funds Are Beating the Market, but Investors Are Still Bailing Out Barrons.com
Nov-07-19 03:03PM  Top Stock Reports for Alibaba, General Electric & Anthem Zacks
Nov-06-19 09:00AM  Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting PR Newswire
07:00AM  Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer PR Newswire
Nov-05-19 04:05PM  This Big Biotech Just Crushed Earnings Views, Unveiled $1 Billion Buyback Investor's Business Daily +6.93%
12:43PM  The Dow Is Up 23 Points as Trade-Deal Hopes Waver Barrons.com
11:56AM  Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength Zacks
07:55AM  Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates Zacks
06:58AM  UPDATE 3-Eylea powers Regeneron's third-quarter profit beat; shares rise Reuters
06:40AM  Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer PR Newswire
06:39AM  Regeneron profit rises nearly 13% on higher demand for eczema drug Dupixent Reuters
06:30AM  Regeneron Reports Third Quarter 2019 Financial and Operating Results PR Newswire
01:38AM  Regeneron Pharma Earnings, Revenue Beat in Q3 Investing.com
Nov-04-19 11:23AM  Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More Zacks
09:58AM  Why Regeneron (REGN) Might Surprise This Earnings Season Zacks
Nov-01-19 11:05AM  Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings? Zacks
10:34AM  Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates Zacks
Oct-31-19 12:20PM  Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 31%? Simply Wall St.
11:34AM  Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales Zacks
Oct-30-19 10:56AM  Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More Zacks
10:34AM  Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y Zacks
Oct-29-19 10:32AM  Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
08:15AM  Dupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis PR Newswire
Oct-28-19 05:10PM  11 Stocks With The Highest Gross Margins Benzinga
11:33AM  Sanofi (SNY) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-19 11:25AM  Amgen (AMGN) to Report Q3 Earnings: What's in the Cards? Zacks
09:51AM  Biotech Fund Investors Are Fleeing, but Biogen Stock and Others Are Rising Barrons.com
07:05AM  Regeneron Ranked #2 in Science Magazine's Top Biopharma Companies to Work For PR Newswire
07:00AM  Regeneron Colleagues Support 150 Community Organizations During Third Annual Day for Doing Good PR Newswire
Oct-24-19 04:08PM  Amgen Cuts The Price Of A Key Drug Prodding A Rival Biotech To Slide Investor's Business Daily
Oct-23-19 10:53AM  Is a Beat in Store for Glaxo (GSK) This Earnings Season? Zacks
Oct-22-19 10:51AM  Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y Zacks
Oct-18-19 08:30AM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
Oct-14-19 11:46AM  3 Undervalued Stocks to Buy According to Goldman Sachs InvestorPlace
Oct-11-19 04:27PM  Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off Investor's Business Daily
Oct-10-19 06:22PM  Hedge Funds Have Never Been This Bullish On Regeneron Pharmaceuticals Inc (REGN) Insider Monkey
10:11AM  Wet AMD Space in Focus: New Drug Approvals & Key Advancements Zacks
09:57AM  Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study Zacks
09:30AM  Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019 PR Newswire
Oct-09-19 12:07PM  New Novartis Drug Tabbed as Blockbuster GuruFocus.com
11:10AM  Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval Zacks
Oct-08-19 04:10PM  Can This Pharma Giant Undercut Regeneron's Biggest Moneymaker? Investor's Business Daily
Oct-03-19 03:02PM  3 Cancer-Fighting Drug Stocks to Buy Right Now InvestorPlace
Oct-01-19 10:23AM  Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Excessively Paying Its CEO? Simply Wall St.
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
10:46AM  Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study Zacks
Sep-29-19 09:15PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 27 GuruFocus.com
Sep-26-19 11:59AM  Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late Zacks
Sep-25-19 11:10AM  Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More Zacks
Sep-24-19 04:19PM  Why Investors Are Beginning To Doubt This Biotech's R&D Prowess Investor's Business Daily
Sep-23-19 12:08PM  Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent Zacks
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorDec 13Option Exercise273.674,0001,094,6804,323Dec 13 04:07 PM
VAGELOS P ROYChairman of the BoardDec 13Sale376.0451,84219,494,489304,485Dec 13 05:43 PM
BROWN MICHAEL SDirectorDec 13Sale373.994,0001,495,968323Dec 13 04:07 PM
Fenimore Christopher R.VP ControllerDec 13Sale376.141,682632,66512,197Dec 13 06:03 PM
VAGELOS P ROYChairman of the BoardDec 12Option Exercise21.25107,6552,287,669412,140Dec 13 05:43 PM
YANCOPOULOS GEORGEPresident and CSODec 12Option Exercise21.25245,2955,212,519521,876Dec 13 04:44 PM
SCHLEIFER LEONARD SPresident & CEODec 12Option Exercise21.25312,4006,638,500571,708Dec 13 04:05 PM
Fenimore Christopher R.VP ControllerDec 12Option Exercise52.033,100161,29315,297Dec 13 06:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Option Exercise33.421,00033,42011,323Dec 02 04:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Sale370.001,000370,00010,323Dec 02 04:03 PM
STAHL NEILEVP Research and DevelopmentNov 26Sale364.074,0061,458,46722,455Nov 26 04:29 PM
STAHL NEILEVP Research and DevelopmentNov 25Option Exercise52.0310,000520,30032,455Nov 26 04:29 PM
VAGELOS P ROYChairman of the BoardNov 25Sale363.8722,1498,059,412304,485Nov 26 04:02 PM
GOLDSTEIN JOSEPH LDirectorNov 22Option Exercise33.421,00033,42011,323Nov 22 04:07 PM
VAGELOS P ROYChairman of the BoardNov 22Option Exercise21.2546,138980,433386,716Nov 26 04:02 PM
GOLDSTEIN JOSEPH LDirectorNov 22Sale360.001,000360,00010,323Nov 22 04:07 PM
GOLDSTEIN JOSEPH LDirectorNov 21Option Exercise33.421,00033,42011,323Nov 22 04:07 PM
GOLDSTEIN JOSEPH LDirectorNov 21Sale350.001,000350,00010,323Nov 22 04:07 PM
BROWN MICHAEL SDirectorNov 12Option Exercise273.674,5001,231,5154,823Nov 13 04:11 PM
BROWN MICHAEL SDirectorNov 12Sale349.004,5001,570,500323Nov 13 04:11 PM
GOLDSTEIN JOSEPH LDirectorNov 08Sale340.441,000340,44010,323Nov 08 05:02 PM
STAHL NEILEVP Research and DevelopmentNov 08Sale338.527,3642,492,88822,455Nov 12 04:05 PM
VAGELOS P ROYChairman of the BoardMay 24Option Exercise21.25153,7923,268,080468,669May 29 04:16 PM
GOLDSTEIN JOSEPH LDirectorMay 15Sale305.931,000305,93011,323May 15 08:42 PM
STAHL NEILEVP Research and DevelopmentMay 14Sale305.749,8533,012,48322,450May 15 04:02 PM
STAHL NEILEVP Research and DevelopmentMay 13Option Exercise52.0325,0001,300,75047,450May 15 04:02 PM
Fenimore Christopher R.VP ControllerApr 18Option Exercise21.253507,4387,446Apr 18 07:04 PM
SCHLEIFER LEONARD SPresident & CEOMar 21Option Exercise21.251002,125424,062Mar 22 04:03 PM
Fenimore Christopher R.VP ControllerJan 18Option Exercise21.251503,1887,246Jan 18 05:01 PM
GOLDSTEIN JOSEPH LDirectorJan 10Option Exercise273.671,791490,14314,114Jan 11 04:06 PM
GOLDSTEIN JOSEPH LDirectorJan 10Sale410.001,791734,31012,323Jan 11 04:06 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise21.2567514,3448,944Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 20Sale358.971,848663,3817,096Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 19Option Exercise52.033,450179,5049,871Dec 20 05:36 PM